Impact of Adherence to Ibrutinib on Clinical Outcomes in Real-World Patients With Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is a B-cell neoplasm with clonal expansion of small lymphocytes. Ibrutinib, an irreversible inhibitor of Bruton tyrosine kinase (BTK), is a first-line treatment option, and recent data suggest that strict adherence is directly related to clinical outcomes. The prim...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Journal of the advanced practitioner in oncology 2021-01, Vol.12 (1), p.20-28
Hauptverfasser:	Garner, Lauren M, Kline, Theresa, Miller, Jordan, Deal, Allison, Zhu, Anqi, Sketch, Margaret R, Coombs, Catherine C, Muluneh, Benyam
Format:	Artikel
Sprache:	eng
Schlagworte:	Research & Scholarship
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!